A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate
Latest Information Update: 12 May 2022
At a glance
- Drugs Odanacatib (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 07 Dec 2014 Status changed from active, no longer recruiting to discontinued as reported by the ClinicalTrials.gov
- 25 Sep 2014 Planned End Date changed from 1 Jul 2016 to 1 Sep 2014 as reported by the ClinicalTrials.gov record.
- 25 Sep 2014 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2014 as reported by the ClinicalTrials.gov record.